COVID-19 Vaccines Clinical Trial
Official title:
T Cell, Antibody and Cytokine Responses to Single and Double Doses of COVID-19 Vaccines in Egyptians
The recent Coronavirus Disease 2019 (COVID-19), has caused a global pandemic, and development of safe, effective vaccines is mandatory to return back to pre pandemic life. Many vaccines have been developed and requested by the authorities after the emergency license issued. The main mechanism of protection is through humoral and cell-mediated immune responses that might reduce the potential for disease development or severity. Cytotoxic T cells clear virus-infected host cells and contribute to control of infection. Preliminary data are now available indicating safty and effecacy of different vaccines . The vaccines were tolerated, with induction of neutralizing antibodies and antigen-specific T cells against the SARS-CoV-2 spike protein. The aim of this work is to evaluate the immune responses in adults, aged 25-65 years, up to 8 weeks after vaccination with a single and double doses live inactivated (Sinopharm), mRNA (Pfizer/ Biontech) and viral vector (Oxford/AZ- ChAdOx1 nCoV-19) vaccines. The Th1- response ( interferon-γ and tumor necrosis factor-α cytokine secretion by CD4+ T cells) and antibody production predominantly of IgG1 and IgG3 subclasses as well as CD8+ T cells mono, polyfunctional and cytotoxic phenotypes, will be also measured.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05918939 -
UNAIR Inactivated COVID-19 Vaccine as Heterologue Booster (Immunobridging Study)
|
Early Phase 1 | |
| Active, not recruiting |
NCT06272253 -
UNAIR Inactivated COVID-19 Vaccine INAVAC as Heterologue Booster (Immunobridging Study) in Adolescent Subjects
|
Early Phase 1 | |
| Recruiting |
NCT05298800 -
Combined Immunization of COVID-19 Inactivated Vaccine With QIV and PPV23
|
Phase 4 | |
| Recruiting |
NCT05185817 -
Effectiveness of COVID-19 Vaccine in Hematopoietic Stem Cell Transplant Patients
|
Phase 2 | |
| Not yet recruiting |
NCT04876885 -
The Future of Viral Communications: Video-Based Health Promotion Strategies for COVID-19 Vaccinations
|
N/A | |
| Completed |
NCT05373459 -
Effect of a Third COVID-19 Booster Among Health Care Workers
|
||
| Active, not recruiting |
NCT05571657 -
COVID-19 Booster Dose Reminder/Recall for Adolescents
|
N/A | |
| Completed |
NCT04888793 -
Immune Response to Anti COVID-19 Vaccine in Immunocompromised Patients: a Cohort Study
|
||
| Completed |
NCT04881396 -
Response of Haemodialysis Patients to BNT162b2 mRNA Cov-19 Vaccine
|
||
| Recruiting |
NCT04871165 -
Analysis of Immunogenicity, Safety and Efficacy of COVID-19 Vaccines in Immunosuppressed Individuals
|
||
| Active, not recruiting |
NCT05293665 -
Platform Trial to Compare Homologous Boost of Authorized COVID-19 Vaccines and Heterologous Boost With UB-612 Vaccine
|
Phase 3 | |
| Active, not recruiting |
NCT05405283 -
Randomized, Single-blinded, Multicenter Trial Comparing the Immune Response to a 2nd Booster Dose of COVID-19 mRNA Vaccine (Pfizer-BioNTech) or Sanofi /GSK B.1.351 Adjuvanted Vaccine in Adults
|
Phase 3 | |
| Recruiting |
NCT05508477 -
UNAIR Inactivated COVID-19 Vaccine Phase III (Immunobridging Study)
|
Phase 3 | |
| Recruiting |
NCT05471635 -
Variables Influencing Anti-COVID-19 Vaccinations Around the World: an Analysis Conducted on Aggregated Data Sourced From Institutional Databases to Understand Whether and How Different Variables Could Affect the Vaccine Coverage (WORLDCOV: Worldwide Determinants of COVID-19 Vaccination)
|
||
| Recruiting |
NCT06282692 -
INAVAC Vaccine Phase III (Immunobridging Study) in Healthy Population Aged 12 to 17 Years Old
|
Phase 3 | |
| Completed |
NCT05406908 -
Intradermal Tozinameran for Patients With Immune-mediated Dermatologic Diseases
|
Phase 4 | |
| Recruiting |
NCT04895007 -
Comparative Evaluation of Covid-19 Vaccines Response
|
||
| Recruiting |
NCT05831826 -
Effectiveness and Safety of the Inactivated COVID-19 Vaccine in Thousands of Patients With Autoimmune Diseases in China
|
||
| Recruiting |
NCT05096260 -
Getting to Yes, Michigan! (G2YMI)
|
N/A | |
| Completed |
NCT04962906 -
Study to Evaluate the Immunogenicity and Safety of Heterologous SARS-CoV-2 Vaccine Schemes
|
Phase 2 |